
News|Videos|August 8, 2023
CARMEN-LC03 and CARMEN-LC04 Trials: Study Design and Anticipated Findings
Author(s)Joshua K. Sabari, MD, Narjust Florez, MD
An overview of the CARMEN-LC03 and CARMEN-LC04 trials investigating tusa in different treatment settings for NSCLC and their impact on treatment approaches is provided.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















